3-hydroxy-5-iodo-indole acetate | 26490-99-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-hydroxy-5-iodo-indole acetate
• 英文别名: 1-(3-Hydroxy-5-iodo-1h-indol-1-yl)ethanone；1-(3-hydroxy-5-iodoindol-1-yl)ethanone
• CAS: 26490-99-3
• 化学式: C₁₀H₈INO₂
• 分子量: 301.084
• InChiKey: UVLGKRYWTYDENO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-hydroxy-5-iodo-indole acetate 、 5,7-diiodo-1-oxaspiro[2.5]octa-4,7-dien-6-one 在 sodium borate buffer 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以81%的产率得到5-iodo-indolyl-3',5'-diiodo-4'-hydroxyl-p-phenol ether
  参考文献：
  名称：

  [EN] HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY
  [FR] PHÉNOLS HALOGÉNÉS UTILISÉS À DES FINS DE DIAGNOSTIC, DE PROTECTION ANTIOXYDANTE ET DE DIFFUSION DE MÉDICAMENTS

  摘要：

  公开号：

  WO2013010102A3
• 作为产物：
  描述：

  3-乙酰氧基-1-乙酰基-5-碘吲哚 在 乙醇 、 水 、 sodium sulfite 作用下， 生成 3-hydroxy-5-iodo-indole acetate
  参考文献：
  名称：

  Holt et al., Journal of the Chemical Society, 1958, p. 1217,1222

  摘要：

  DOI：

文献信息

• Halogenated Phenols for Diagnostics, Antioxidant Protection and Drug Delivery
  申请人：Latham Keith R.

  公开号：US20180117164A1

  公开（公告）日：2018-05-03

  The present invention provides compositions and methods for the targeted delivery, release and/or formation of a drug compound at a target site(s) within the body of an individual, such as a diseased and/or inflamed tissue in the body of the individual. These compositions may comprise a halogenated phenol ring cleavably linked to a core structure of a drug compound. Due to the variety of substituents that may be utilized in forming the different types of linkages, numerous examples of drug compounds linked to a halogenated phenol ring are proposed. The present invention further provides compositions comprising halogenated phenol starting compounds that do not undergo cleavage during a dehalogenation reaction to form a drug compound in a targeted tissue when administered to an individual. Methods of administering these non-cleaving compounds are further provided.

  本发明提供了用于在个体体内的目标部位（如个体体内的患病和/或发炎组织）定向传递、释放和/或形成药物化合物的组合物和方法。这些组合物可能包括可被切断连接到药物化合物的核结构的卤代酚环。由于在形成不同类型的连接时可以利用的取代基的多样性，提出了与卤代酚环连接的药物化合物的众多示例。本发明还提供了包含卤代酚起始化合物的组合物，当向个体施用时，在靶向组织中不会在去卤反应期间发生切断以形成药物化合物。进一步提供了施用这些非切断化合物的方法。
• METHOD AND COMPOSITION FOR THE TREATMENT OF CANCER BY THE ENZYMANTIC CONVERSION OF SOLUBLE RADIOACTIVE TOXIC PRECIPITATES IN THE CANCER
  申请人：——

  公开号：US20020022003A1

  公开（公告）日：2002-02-21

  A method for the treatment of cancer is disclosed which is capable of directing supra-lethal doses of radiation, called Hot-Spots, virtually exclusively to the cancer. The present invention involves a multi-step therapy process and includes a class of novel chemical agents. In accordance with the present invention, it was discovered that soluble precipitable materials can be made to accumulate as non-digestible precipitates in targeted cells as a result of enzyme action within the targeted cells. Accumulation is achieved by administering to the living host a soluble binary reagent made by attaching a targeting agent to a novel chemical agent which is a soluble precipitable material. The binary reagent binds to antigenic receptors on targeted cells which endocytose the binary reagent and transport it into the lysosomes where enzymes detach the soluble precipitable material from the targeting agent, causing it to precipitate, accumulate, and be retained in the cells. Increasing amounts of precipitate can be made to accumulate in cells by continuing the administration of the binary reagent. The accumulated precipitate is relocated to the extra-cellular fluid by selectively killing a fraction of cancer cells. Now relocated in the extra-cellular fluid of the cancer, the precipitate is used as a “platform” from which to generate Hot-Spots. A bispecific reagent with a non-mammalian enzyme moiety is made to bind to the precipitate. A soluble radioactive material is administered which is converted by the enzyme moiety of the bound bispecific reagent into a new form which is retained adjacent to the precipitate for an extended period of time, thereby generating Hot-Spots which non-selectively kill all cells adjacent to the precipitate in the extra-cellular fluid of the cancer.

  本发明公开了一种治疗癌症的方法，该方法能够将超致命剂量的辐射（称为 "热点"）几乎完全导向癌症。本发明涉及一个多步骤治疗过程，包括一类新型化学制剂。根据本发明，人们发现可溶性沉淀物可以在靶细胞内酶的作用下，以非消化沉淀物的形式在靶细胞内积聚。可溶性沉淀物的积累是通过向活体宿主施用一种可溶性二元试剂来实现的，该试剂是通过将一种靶向药剂与一种新型化学药剂（一种可溶性沉淀物）相连而制成的。二元试剂与靶细胞上的抗原受体结合，靶细胞内吞二元试剂并将其转运到溶酶体中，在溶酶体中酶将可溶性沉淀物与靶向剂分离，使其沉淀、积累并保留在细胞中。通过继续施用二元试剂，可使沉淀物在细胞中的积累量不断增加。通过选择性地杀死一部分癌细胞，可将积累的沉淀转移到细胞外液中。现在，沉淀转移到了癌细胞的细胞外液中，可用作生成热点的 "平台"。一种带有非哺乳动物酶分子的双特异性试剂与沉淀结合。施用一种可溶性放射性物质，这种物质会被结合的双特异性试剂的酶分子转化成一种新的形式，并在沉淀物附近保留较长时间，从而产生热斑，非选择性地杀死癌症细胞外液中沉淀物附近的所有细胞。
• METHOD AND COMPOSITION FOR TREATING CANCER BY CONVERTING SOLUBLE RADIOACTIVE TOXIC AGENTS INTO INSOLUBLE RADIOACTIVE TOXIC PRECIPITATES VIA THE ACTION OF NON-MAMMALIAN ENZYMES BOUND TO THE NON- ENDOCYTOSING RECEPTORS OF TARGET CELLS
  申请人：——

  公开号：US20030045458A1

  公开（公告）日：2003-03-06

  A method for the treatment of cancer is disclosed which is capable of directing supra-lethal doses of radiation, called Hot-Spots, virtually exclusively to the cancer. The present invention involves a multi-step therapy process and includes a class of novel chemical agents. In accordance with the present invention, it was discovered that soluble precipitable materials can be made to accumulate as non-digestible precipitates in the extra-cellular fluid in the cancer region as a result of non-mammalian enzyme action. Precipitate accumulation is achieved by the prior administration of a bispecific reagent with a non-mammalian enzyme moiety and a targeting agent capable of binding to non-endocytosing receptors of target cancer cells. A soluble radioactive toxic therapeutic agent is then administered, the soluble toxic therapeutic agent being adapted to be converted by the non-mammalian enzyme moiety of the bound bispecific reagent into a new form which is retained adjacent to the target cancer cells for an extended period of time, thereby generating Hot-Spots which non-selectively kill all cells in the cancer region adjacent to the bispecific reagent.

  本发明公开了一种治疗癌症的方法，该方法能够将超致命剂量的辐射（称为 "热点"）几乎完全导向癌症。本发明涉及一个多步骤治疗过程，包括一类新型化学制剂。根据本发明，人们发现，由于非哺乳动物酶的作用，可溶性沉淀物可以作为非消化沉淀物积聚在癌症区域的细胞外液中。沉淀物的积累是通过事先施用双特异性试剂来实现的，这种试剂具有非哺乳动物酶分子和能够与靶癌细胞的非内吞受体结合的靶向剂。然后施用一种可溶性放射性毒性治疗剂，这种可溶性毒性治疗剂可被结合的双特异性试剂的非哺乳动物酶分子转化为一种新的形式，这种新形式可在靶癌细胞附近保留较长时间，从而产生热斑，非选择性地杀死双特异性试剂附近癌区的所有细胞。
• Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
  申请人：——

  公开号：US20030068382A1

  公开（公告）日：2003-04-10

  A method for the treatment of cancer is disclosed which is capable of directing supra-lethal doses of radiation, called Hot-Spots, virtually exclusively to the cancer. The present invention involves a multi-step therapy process and includes a class of novel chemical agents. In accordance with the present invention, it was discovered that soluble precipitable materials can be made to accumulate as non-digestible precipitates in targeted cells as a result of enzyme action within the targeted cells. Accumulation is achieved by administering to the living host a soluble binary reagent made by attaching a targeting agent to a novel chemical agent which is a soluble precipitable material. The binary reagent binds to antigenic receptors on targeted cells which endocytose the binary reagent and transport it into the lysosomes where enzymes detach the soluble precipitable material from the targeting agent, causing it to precipitate, accumulate, and be retained in the cells. Increasing amounts of precipitate can be made to accumulate in cells by continuing the administration of the binary reagent. The accumulated precipitate is relocated to the extra-cellular fluid by selectively killing a fraction of cancer cells. Now relocated in the extra-cellular fluid of the cancer, the precipitate is used as a “platform” from which to generate Hot-Spots. A bispecific reagent with a non-mammalian enzyme moiety is made to bind to the precipitate. A soluble radioactive material is administered which is converted by the enzyme moiety of the bound bispecific reagent into a new form which is retained adjacent to the precipitate for an extended period of time, thereby generating Hot-Spots which non-selectively kill all cells adjacent to the precipitate in the extra-cellular fluid of the cancer.

  本发明公开了一种治疗癌症的方法，该方法能够将超致命剂量的辐射（称为 "热点"）几乎完全导向癌症。本发明涉及一个多步骤治疗过程，包括一类新型化学制剂。根据本发明，人们发现可溶性沉淀物可以在靶细胞内酶的作用下，以非消化沉淀物的形式在靶细胞内积聚。可溶性沉淀物的积累是通过向活体宿主施用一种可溶性二元试剂来实现的，该试剂是通过将一种靶向药剂与一种新型化学药剂（一种可溶性沉淀物）相连而制成的。二元试剂与靶细胞上的抗原受体结合，靶细胞内吞二元试剂并将其转运到溶酶体中，在溶酶体中酶将可溶性沉淀物与靶向剂分离，使其沉淀、积累并保留在细胞中。通过继续施用二元试剂，可使沉淀物在细胞中的积累量不断增加。通过选择性地杀死一部分癌细胞，可将积累的沉淀转移到细胞外液中。现在，沉淀转移到了癌细胞的细胞外液中，可用作生成热点的 "平台"。一种带有非哺乳动物酶分子的双特异性试剂与沉淀结合。施用一种可溶性放射性物质，这种物质会被结合的双特异性试剂的酶分子转化成一种新的形式，并在沉淀物附近保留较长时间，从而产生热斑，非选择性地杀死癌症细胞外液中沉淀物附近的所有细胞。
• Method and composition for treating cancer by converting soluble radioactive toxic agents into insoluble radioactive toxic precipitates via the action of non-mammalian enzymes bound to the non-endocytosing receptors of target cells
  申请人：Rose Samuel

  公开号：US20050113290A1

  公开（公告）日：2005-05-26

  A method for the treatment of cancer is disclosed which is capable of directing supra-lethal doses of radiation, called Hot-Spots, virtually exclusively to the cancer. The present invention involves a multi-step therapy process and includes a class of novel chemical agent. In accordance with the present invention, it was discovered that soluble precipitable materials can be made to accumulate as non-digestible precipitates in the extra-cellular fluid in the cancer region as a result of non-mammalian enzyme action. Precipitate accumulation is achieved by prior administration of a bispecific reagent with a non-mammalian enzyme moiety and a agent capable of binding to non-endocytosing receptors of target cancer cells. A soluble radioactive toxic therapeutic agent is then administered, the soluble toxic therapeutic agent being adapted to be converted by the non-mammalian enzyme moiety of the bound bispecific reagent into a new form which is retained adjacent to the target cancer cells for an extended period of time, thereby generating Hot-Spots which non-selectively kill all cells in the cancer region adjacent to the bispecific reagent.

  本发明公开了一种治疗癌症的方法，该方法能够将超致命剂量的辐射（称为 "热点"）几乎完全导向癌症。本发明涉及一个多步骤治疗过程，包括一类新型化学制剂。根据本发明，人们发现，由于非哺乳动物酶的作用，可溶性沉淀物可以作为非消化沉淀物积聚在癌症区域的细胞外液中。沉淀物的积累是通过事先施用一种双特异性试剂来实现的，该试剂具有非哺乳动物酶分子和一种能够与靶癌细胞的非内吞受体结合的药剂。然后施用一种可溶性放射性毒性治疗剂，这种可溶性毒性治疗剂可被结合的双特异性试剂的非哺乳动物酶分子转化为一种新的形式，这种新形式会在靶癌细胞附近保留较长时间，从而产生热斑，非选择性地杀死双特异性试剂附近癌变区域的所有细胞。